INNOCARE (09969) files for market approval of a new generation pan-TRK inhibitor.

On April 16, INNOCARE (09969) announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the new drug application (NDA) for the new generation pan-TRK inhibitor Zurletrectinib (ICP-723) for the treatment of advanced solid tumors in adults and adolescents (ages 12-<18 years) carrying NTRK fusion genes. Zurletrectinib is a pan-TRK inhibitor independently developed by INNOCARE, which can effectively inhibit TRKA, TRKB, TRKC, and overcome acquired resistance to TRKA mutations such as G595R and G667C, thus overcoming the resistance seen with first-generation TRK inhibitors.